Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 inhibitors) in clinical trials for cancer treatment

Journal of Medicinal Chemistry

Volumn 58, Issue 3, 2015, Pages 1038-1052

  Zhao, Yujun ^a   Aguilar, Angelo ^a   Bernard, Denzil ^a   Wang, Shaomeng ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IDASANUTLIN; MI 77301; PROTEIN MDM2; PROTEIN MDM2 INHIBITOR; PROTEIN P53; SAR 405838; UNCLASSIFIED DRUG; [2 (4 TERT BUTYL 2 ETHOXYPHENYL) 4,5 BIS(4 CHLOROPHENYL) 4,5 DIHYDRO 4,5 DIMETHYL 1H IMIDAZOL 1 YL][4 [3 (METHYLSULFONYL)PROPYL] 1 PIPERAZINYL]METHANONE; ENZYME INHIBITOR; MOLECULAR LIBRARY; PROTEIN BINDING;

ANTINEOPLASTIC ACTIVITY; CANCER THERAPY; CLINICAL TRIAL (TOPIC); DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; PROTEIN PROTEIN INTERACTION; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; METABOLISM; MOLECULAR LIBRARY; NEOPLASMS; PHARMACOLOGY; STRUCTURE ACTIVITY RELATION; SYNTHESIS; THERAPEUTIC USE;

ANIMALS; CLINICAL TRIALS AS TOPIC; ENZYME INHIBITORS; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NEOPLASMS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MDM2; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84922813362     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm501092z     Document Type: Review

References (79)

1. Wade, M.; Li, Y. C.; Wahl, G. M. MDM2, MDMX and p53 in oncogenesis and cancer therapy Nat. Rev. Cancer 2013, 13, 83-96
2. Vousden, K. H.; Lu, X. Live or let die: the cells response to p53 Nat. Rev. Cancer 2002, 2, 594-604
3. Stiewe, T. The p53 family in differentiation and tumorigenesis Nat. Rev. Cancer 2007, 7, 165-168
4. Toledo, F.; Wahl, G. M. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas Nat. Rev. Cancer 2006, 6, 909-923
5. Brown, C. J.; Lain, S.; Verma, C. S.; Fersht, A. R.; Lane, D. P. Awakening guardian angels: drugging the p53 pathway Nat. Rev. Cancer 2009, 9, 862-873
6. Kemp, C. J.; Donehower, L. A.; Bradley, A.; Balmain, A. Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors Cell 1993, 74, 813-822
7. Feki, A.; Irminger-Finger, I. Mutational spectrum of p53 mutations in primary breast and ovarian tumors Crit. Rev. Oncol. Hematol. 2004, 52, 103-116
8. Jones, S. N.; Roe, A. E.; Donehower, L. A.; Bradley, A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53 Nature 1995, 378, 206-208
9. Montes de Oca Luna, R.; Wagner, D. S.; Lozano, G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53 Nature 1995, 378, 203-206
10. Freedman, D. A.; Wu, L.; Levine, A. J. Functions of the MDM2 oncoprotein Cell. Mol. Life Sci. 1999, 55, 96-107
11. Wu, X.; Bayle, J. H.; Olson, D.; Levine, A. J. The p53-mdm-2 autoregulatory feedback loop Genes Dev. 1993, 7, 1126-1132
12. Juven-Gershon, T.; Oren, M. Mdm2: the ups and downs Mol. Med. 1999, 5, 71-83
13. Ganguli, G.; Abecassis, J.; Wasylyk, B. MDM2 induces hyperplasia and premalignant lesions when expressed in the basal layer of the epidermis EMBO J. 2000, 19, 5135-5147
14. Momand, J.; Jung, D.; Wilczynski, S.; Niland, J. The MDM2 gene amplification database Nucleic Acids Res. 1998, 26, 3453-3459
15. Bond, G. L.; Hu, W.; Bond, E. E.; Robins, H.; Lutzker, S. G.; Arva, N. C.; Bargonetti, J.; Bartel, F.; Taubert, H.; Wuerl, P.; Onel, K.; Yip, L.; Hwang, S. J.; Strong, L. C.; Lozano, G.; Levine, A. J. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans Cell 2004, 119, 591-602
16. Bond, G. L.; Hu, W.; Levine, A. J. MDM2 is a central node in the p53 pathway: 12 years and counting Curr. Cancer Drug Targets 2005, 5, 3-8
17. Capoulade, C.; Bressac-de Paillerets, B.; Lefrere, I.; Ronsin, M.; Feunteun, J.; Tursz, T.; Wiels, J. Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitts lymphoma cells Oncogene 1998, 16, 1603-1610
18. Momand, J.; Wu, H. H.; Dasgupta, G. MDM2-master regulator of the p53 tumor suppressor protein Gene 2000, 242, 15-29
19. Shvarts, A.; Steegenga, W. T.; Riteco, N.; vanLaar, T.; Dekker, P.; Bazuine, M.; vanHam, R. C. A.; vanOordt, W. V.; Hateboer, G.; vanderEb, A. J.; Jochemsen, A. G. MDMX: a novel p53-binding protein with some functional properties of MDM2 EMBO J. 1996, 15, 5349-5357
20. Oliner, J. D.; Kinzler, K. W.; Meltzer, P. S.; George, D. L.; Vogelstein, B. Amplification of a gene encoding a p53-associated protein in human sarcomas Nature 1992, 358, 80-83
21. Kussie, P. H.; Gorina, S.; Marechal, V.; Elenbaas, B.; Moreau, J.; Levine, A. J.; Pavletich, N. P. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain Science 1996, 274, 948-953
22. Riedinger, C.; McDonnell, J. M. Inhibitors of MDM2 and MDMX: a structural perspective Future Med. Chem. 2009, 1, 1075-1094
23. Millard, M.; Pathania, D.; Grande, F.; Xu, S.; Neamati, N. Small-molecule inhibitors of p53-MDM2 interaction: the 2006-2010 update Curr. Pharm. Des 2011, 17, 536-559
24. Vassilev, L. T. MDM2 inhibitors for cancer therapy Trends Mol. Med. 2007, 13, 23-31
25. Khoury, K.; Popowicz, G. M.; Holak, T. A.; Domling, A. The p53-MDM2/MDMX axis-a chemotype perspective MedChemComm 2011, 2, 246-260
26. Wang, S.; Zhao, Y.; Bernard, D.; Aguilar, A.; Kumar, S. Targeting the MDM2-p53 protein-protein interaction for new cancer therapeutics Top Med. Chem. 2012, 8, 57-80
27. Lane, D. P.; Cheok, C. F.; Lain, S. p53-based cancer therapy Cold Spring Harbor Perspect. Biol. 2010, 2, a001222
28. Popowicz, G. M.; Domling, A.; Holak, T. A. The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious Angew. Chem., Int. Ed. 2011, 50, 2680-2688
29. Dickens, M. P.; Fitzgerald, R.; Fischer, P. M. Small-molecule inhibitors of MDM2 as new anticancer therapeutics Semin. Cancer Biol. 2010, 20, 10-18
30. Hoe, K. K.; Verma, C. S.; Lane, D. P. Drugging the p53 pathway: understanding the route to clinical efficacy Nat. Rev. Drug Discovery 2014, 13, 217-236
31. Vu, B.; Wovkulich, P.; Pizzolato, G.; Lovey, A.; Ding, Q.; Jiang, N.; Liu, J.-J.; Zhao, C.; Glenn, K.; Wen, Y.; Tovar, C.; Packman, K.; Vassilev, L.; Graves, B. Discovery of RG7112: a small-molecule MDM2 inhibitor in clinical development ACS Med. Chem. Lett. 2013, 4, 466-469
32. Ding, Q.; Zhang, Z.; Liu, J.-J.; Jiang, N.; Zhang, J.; Ross, T. M.; Chu, X.-J.; Bartkovitz, D.; Podlaski, F.; Janson, C.; Tovar, C.; Filipovic, Z. M.; Higgins, B.; Glenn, K.; Packman, K.; Vassilev, L. T.; Graves, B. Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development J. Med. Chem. 2013, 56, 5979-5983
33. Siu, L. L.; Italiano, A.; Miller, W. H., Jr; Blay, J. Y.; Gietema, J. A.; Bang, Y. J.; Mileshkin, L. R.; Hirte, H. W.; Reckner, M.; Higgins, B.; Jukofsky, L.; Blotner, S.; Zhi, J.; Middleton, S.; Nichols, G. L.; Chen, L. C. Phase 1 dose escalation, food effect, and biomarker study of RG7388, a more potent second-generation MDM2 antagonist, in patients (pts) with solid tumors J. Clin Oncol 2014, 32 (Suppl.) 2535
34. Wang, S.; Sun, W.; Zhao, Y.; McEachern, D.; Meaux, I.; Barrière, C.; Stuckey, J.; Meagher, J.; Bai, B.; Liu, L.; Hoffman-Luca, C. G.; Lu, J.; Shangary, S.; Yu, S. H.; Bernard, D.; Aguilar, A.; Dos-Santos, O.; Besret, L.; Guerif, S.; Pannier, P.; Gorge-Bernat, D.; Debussche, L. SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression Cancer Res. 2014, 74, 5855-5865
35. Sun, D.; Li, Z.; Rew, Y.; Gribble, M.; Bartberger, M. D.; Beck, H. P.; Canon, J.; Chen, A.; Chen, X.; Chow, D.; Deignan, J.; Duquette, J.; Eksterowicz, J.; Fisher, B.; Fox, B. M.; Fu, J.; Gonzalez, A. Z.; Gonzalez-Lopez De Turiso, F.; Houze, J. B.; Huang, X.; Jiang, M.; Jin, L.; Kayser, F.; Liu, J.; Lo, M.-C.; Long, A. M.; Lucas, B.; McGee, L. R.; McIntosh, J.; Mihalic, J.; Oliner, J. D.; Osgood, T.; Peterson, M. L.; Roveto, P.; Saiki, A. Y.; Shaffer, P.; Toteva, M.; Wang, Y.; Wang, Y. C.; Wortman, S.; Yakowec, P.; Yan, X.; Ye, Q.; Yu, D.; Yu, M.; Zhao, X.; Zhou, J.; Zhu, J.; Olson, S. H.; Medina, J. C. Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 Inhibitor in clinical development J. Med. Chem. 2014, 57, 1454-1472
36. Vassilev, L. T.; Vu, B. T.; Graves, B.; Carvajal, D.; Podlaski, F.; Filipovic, Z.; Kong, N.; Kammlott, U.; Lukacs, C.; Klein, C.; Fotouhi, N.; Liu, E. A. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 Science 2004, 303, 844-848
37. Ray-Coquard, I.; Blay, J. Y.; Italiano, A.; Le Cesne, A.; Penel, N.; Zhi, J.; Heil, F.; Rueger, R.; Graves, B.; Ding, M.; Geho, D.; Middleton, S. A.; Vassilev, L. T.; Nichols, G. L.; Bui, B. N. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study Lancet Oncol. 2012, 13, 1133-1140
38. Shangary, S.; Qin, D.; McEachern, D.; Liu, M.; Miller, R. S.; Qiu, S.; Nikolovska-Coleska, Z.; Ding, K.; Wang, G.; Chen, J.; Bernard, D.; Zhang, J.; Lu, Y.; Gu, Q.; Shah, R. B.; Pienta, K. J.; Ling, X.; Kang, S.; Guo, M.; Sun, Y.; Yang, D.; Wang, S. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 3933-3938
39. Ding, K.; Lu, Y.; Nikolovska-Coleska, Z.; Qiu, S.; Ding, Y. S.; Gao, W.; Stuckey, J.; Krajewski, K.; Roller, P. P.; Tomita, Y.; Parrish, D. A.; Deschamps, J. R.; Wang, S. M. Structure-based design of potent non-peptide MDM2 inhibitors J. Am. Chem. Soc. 2005, 127, 10130-10131
40. Zhao, Y.; Yu, S.; Sun, W.; Liu, L.; Lu, J.; McEachern, D.; Shargary, S.; Bernard, D.; Li, X.; Zhao, T.; Zou, P.; Sun, D.; Wang, S. A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice J. Med. Chem. 2013, 56, 5553-5561
41. Yu, S. H.; Qin, D. G.; Shangary, S.; Chen, J. Y.; Wang, G. P.; Ding, K.; McEachern, D.; Qiu, S.; Nikolovska-Coleska, Z.; Miller, R.; Kang, S. M.; Yang, D. J.; Wang, S. M. Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction J. Med. Chem. 2009, 52, 7970-7973
42. Carry, J.-C.; Garcia-Echeverria, C. Inhibitors of the p53/hdm2 protein-protein interaction-path to the clinic Bioorg. Med. Chem. Lett. 2013, 23, 2480-2485
43. Wang, S.; Zhao, Y.; Sun, W.; Kumar, S.; Leopold, L.; Debussche, L.; Barriere, C.; Carry, J. C.; Amaning, K. Spiro-oxindole MDM2 antagonists. PCT Patent Publication Number WO 2012/06022 A2, 2012.
44. Rew, Y.; Sun, D. Q.; De Turiso, F. G. L.; Bartberger, M. D.; Beck, H. P.; Canon, J.; Chen, A.; Chow, D.; Deignan, J.; Fox, B. M.; Gustin, D.; Huang, X.; Jiang, M.; Jiao, X. Y.; Jin, L. X.; Kayser, F.; Kopecky, D. J.; Li, Y. H.; Lo, M. C.; Long, A. M.; Michelsen, K.; Oliner, J. D.; Osgood, T.; Ragains, M.; Saiki, A. Y.; Schneider, S.; Toteva, M.; Yakowec, P.; Yan, X. L.; Ye, Q. P.; Yu, D. Y.; Zhao, X. N.; Zhou, J.; Medina, J. C.; Olson, S. H. Structure-based design of novel inhibitors of the MDM2-p53 interaction J. Med. Chem. 2012, 55, 4936-4954
45. Michelsen, K.; Jordan, J. B.; Lewis, J.; Long, A. M.; Yang, E.; Rew, Y.; Zhou, J.; Yakowec, P.; Schnier, P. D.; Huang, X.; Poppe, L. Ordering of the N-terminus of human MDM2 by small molecule inhibitors J. Am. Chem. Soc. 2012, 134, 17059-17067
46. Lucas, B. S.; Fisher, B.; McGee, L. R.; Olson, S. H.; Medina, J. C.; Cheung, E. An expeditious synthesis of the MDM2-p53 inhibitor AM-8553 J. Am. Chem. Soc. 2012, 134, 12855-12860
47. Perez-Moreno, P.; Brambilla, E.; Thomas, R.; Soria, J. C. Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities Clin. Cancer Res. 2012, 18, 2443-2451
48. Raboisson, P.; Marugan, J. J.; Schubert, C.; Koblish, H. K.; Lu, T.; Zhao, S.; Player, M. R.; Maroney, A. C.; Reed, R. L.; Huebert, N. D.; Lattanze, J.; Parks, D. J.; Cummings, M. D. Structure-based design, synthesis, and biological evaluation of novel 1,4-diazepines as HDM2 antagonists Bioorg. Med. Chem. Lett. 2005, 15, 1857-1861
49. Parks, D. J.; LaFrance, L. V.; Calvo, R. R.; Milkiewicz, K. L.; Marugan, J. J.; Raboisson, P.; Schubert, C.; Koblish, H. K.; Zhao, S.; Franks, C. F.; Lattanze, J.; Carver, T. E.; Cummings, M. D.; Maguire, D.; Grasberger, B. L.; Maroney, A. C.; Lu, T. Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein-protein interaction through structure-based drug design Bioorg. Med. Chem. Lett. 2006, 16, 3310-3314
50. Grasberger, B. L.; Lu, T.; Schubert, C.; Parks, D. J.; Carver, T. E.; Koblish, H. K.; Cummings, M. D.; LaFrance, L. V.; Milkiewicz, K. L.; Calvo, R. R.; Maguire, D.; Lattanze, J.; Franks, C. F.; Zhao, S.; Ramachandren, K.; Bylebyl, G. R.; Zhang, M.; Manthey, C. L.; Petrella, E. C.; Pantoliano, M. W.; Deckman, I. C.; Spurlino, J. C.; Maroney, A. C.; Tomczuk, B. E.; Molloy, C. J.; Bone, R. F. Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells J. Med. Chem. 2005, 48, 909-912
51. Marugan, J. J.; Leonard, K.; Raboisson, P.; Gushue, J. M.; Calvo, R.; Koblish, H. K.; Lattanze, J.; Zhao, S.; Cummings, M. D.; Player, M. R.; Schubert, C.; Maroney, A. C.; Lu, T. Enantiomerically pure 1,4-benzodiazepine-2,5-diones as Hdm2 antagonists Bioorg. Med. Chem. Lett. 2006, 16, 3115-3120
52. Hardcastle, I. R.; Liu, J. F.; Valeur, E.; Watson, A.; Ahmed, S. U.; Blackburn, T. J.; Bennaceur, K.; Clegg, W.; Drummond, C.; Endicott, J. A.; Golding, B. T.; Griffin, R. J.; Gruber, J.; Haggerty, K.; Harrington, R. W.; Hutton, C.; Kemp, S.; Lu, X. C.; McDonnell, J. M.; Newell, D. R.; Noble, M. E. M.; Payne, S. L.; Revill, C. H.; Riedinger, C.; Xu, Q.; Lunec, J. Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency J. Med. Chem. 2011, 54, 1233-1243
53. Beck, H. P.; DeGraffenreid, M.; Fox, B.; Allen, J. G.; Rew, Y.; Schneider, S.; Saiki, A. Y.; Yu, D.; Oliner, J. D.; Salyers, K.; Ye, Q.; Olson, S. Improvement of the synthesis and pharmacokinetic properties of chromenotriazolopyrimidine MDM2-p53 protein-protein inhibitors Bioorg. Med. Chem. Lett. 2011, 21, 2752-2755
54. Bertamino, A.; Soprano, M.; Musella, S.; Rusciano, M. R.; Sala, M.; Vernieri, E.; Di Sarno, V.; Limatola, A.; Carotenuto, A.; Cosconati, S.; Grieco, P.; Novellino, E.; Illario, M.; Campiglia, P.; Gomez-Monterrey, I. Synthesis, in vitro, and in cell studies of a new series of [indoline-3,2′-thiazolidine]-based p53 modulators J. Med. Chem. 2013, 56, 5407-5421
55. Miyazaki, M.; Naito, H.; Sugimoto, Y.; Yoshida, K.; Kawato, H.; Okayama, T.; Shimizu, H.; Kitagawa, M.; Seki, T.; Fukutake, S.; Shiose, Y.; Aonuma, M.; Soga, T. Synthesis and evaluation of novel orally active p53-MDM2 interaction inhibitors Bioorg. Med. Chem. 2013, 21, 4319-4331
56. Furet, P.; Chene, P.; De Pover, A.; Valat, T. S.; Lisztwan, J. H.; Kallen, J.; Masuya, K. The central valine concept provides an entry in a new class of non peptide inhibitors of the p53-MDM2 interaction Bioorg. Med. Chem. Lett. 2012, 22, 3498-3502
57. Czarna, A.; Beck, B.; Srivastava, S.; Popowicz, G. M.; Wolf, S.; Huang, Y.; Bista, M.; Holak, T. A.; Domling, A. Robust generation of lead compounds for protein-protein interactions by computational and MCR chemistry: p53/Hdm2 antagonists Angew. Chem., Int. Ed. 2010, 49, 5352-5356
58. Huang, Y.; Wolf, S.; Koes, D.; Popowicz, G. M.; Camacho, C. J.; Holak, T. A.; Domling, A. Exhaustive fluorine scanning toward potent p53-Mdm2 antagonists ChemMedChem 2012, 7, 49-52
59. Zhuang, C.; Miao, Z.; Zhu, L.; Dong, G.; Guo, Z.; Wang, S.; Zhang, Y.; Wu, Y.; Yao, J.; Sheng, C.; Zhang, W. Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction J. Med. Chem. 2012, 55, 9630-9642
60. Wang, W. S.; Zhu, X. L.; Hong, X. Q.; Zheng, L.; Zhu, H.; Hu, Y. Z. Identification of novel inhibitors of p53-MDM2 interaction facilitated by pharmacophore-based virtual screening combining molecular docking strategy MedChemComm 2013, 4, 411-416
61. Ma, Y.; Lahue, B. R.; Gibeau, C. R.; Shipps, G. W., Jr.; Bogen, S. L.; Wang, Y.; Guo, Z.; Guzi, T. J. Pivotal role of an aliphatic side chain in the development of an HDM2 inhibitor ACS Med. Chem. Lett. 2014, 5, 572-575
62. Pan, W.; Lahue, B. R.; Ma, Y.; Nair, L. G.; Shipps, G. W., Jr.; Wang, Y.; Doll, R.; Bogen, S. L. Core modification of substituted piperidines as novel inhibitors of HDM2-p53 protein-protein interaction Bioorg. Med. Chem. Lett. 2014, 24, 1983-1986
63. Gonzalez, A. Z.; Eksterowicz, J.; Bartberger, M. D.; Beck, H. P.; Canon, J.; Chen, A.; Chow, D.; Duquette, J.; Fox, B. M.; Fu, J.; Huang, X.; Houze, J. B.; Jin, L.; Li, Y.; Li, Z.; Ling, Y.; Lo, M.-C.; Long, A. M.; McGee, L. R.; McIntosh, J.; McMinn, D. L.; Oliner, J. D.; Osgood, T.; Rew, Y.; Saiki, A. Y.; Shaffer, P.; Wortman, S.; Yakowec, P.; Yan, X.; Ye, Q.; Yu, D.; Zhao, X.; Zhou, J.; Olson, S. H.; Medina, J. C.; Sun, D. Selective and potent morpholinone inhibitors of the MDM2-p53 protein-protein interaction J. Med. Chem. 2014, 57, 2472-2488
64. Gonzalez, A. Z.; Li, Z.; Beck, H. P.; Canon, J.; Chen, A.; Chow, D.; Duquette, J.; Eksterowicz, J.; Fox, B. M.; Fu, J.; Huang, X.; Houze, J.; Jin, L.; Li, Y.; Ling, Y.; Lo, M.-C.; Long, A. M.; McGee, L. R.; McIntosh, J.; Oliner, J. D.; Osgood, T.; Rew, Y.; Saiki, A. Y.; Shaffer, P.; Wortman, S.; Yakowec, P.; Yan, X.; Ye, Q.; Yu, D.; Zhao, X.; Zhou, J.; Olson, S. H.; Sun, D.; Medina, J. C. Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres J. Med. Chem. 2014, 57, 2963-2988
65. Zhang, Z.; Chu, X.-J.; Liu, J.-J.; Ding, Q.; Zhang, J.; Bartkovitz, D.; Jiang, N.; Karnachi, P.; So, S.-S.; Tovar, C.; Filipovic, Z. M.; Higgins, B.; Glenn, K.; Packman, K.; Vassilev, L.; Graves, B. Discovery of potent and orally active p53-MDM2 inhibitors RO5353 and RO2468 for potential clinical development ACS Med. Chem. Lett. 2013, 5, 124-127
66. Hardcastle, I. R.; Ahmed, S. U.; Atkins, H.; Farnie, G.; Golding, B. T.; Griffin, R. J.; Guyenne, S.; Hutton, C.; Kallblad, P.; Kemp, S. J.; Kitching, M. S.; Newell, D. R.; Norbedo, S.; Northen, J. S.; Reid, R. J.; Saravanan, K.; Willems, H. M.; Lunec, J. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold J. Med. Chem. 2006, 49, 6209-6221
67. Hardcastle, I. R.; Ahmed, S. U.; Atkins, H.; Calvert, A. H.; Curtin, N. J.; Farnie, G.; Golding, B. T.; Griffin, R. J.; Guyenne, S.; Hutton, C.; Kallblad, P.; Kemp, S. J.; Kitching, M. S.; Newell, D. R.; Norbedo, S.; Northen, J. S.; Reid, R. J.; Saravanan, K.; Willems, H. M.; Lunec, J. Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction Bioorg. Med. Chem. Lett. 2005, 15, 1515-1520
68. Allen, J. G.; Bourbeau, M. P.; Wohlhieter, G. E.; Bartberger, M. D.; Michelsen, K.; Hungate, R.; Gadwood, R. C.; Gaston, R. D.; Evans, B.; Mann, L. W.; Matison, M. E.; Schneider, S.; Huang, X.; Yu, D.; Andrews, P. S.; Reichelt, A.; Long, A. M.; Yakowec, P.; Yang, E. Y.; Lee, T. A.; Oliner, J. D. Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction J. Med. Chem. 2009, 52, 7044-7053
69. Gomez-Monterrey, I.; Bertamino, A.; Porta, A.; Carotenuto, A.; Musella, S.; Aquino, C.; Granata, I.; Sala, M.; Brancaccio, D.; Picone, D.; Ercole, C.; Stiuso, P.; Campiglia, P.; Grieco, P.; Ianelli, P.; Maresca, B.; Novellino, E. Identification of the spiro(oxindole-3,3′-thiazolidine)-based derivatives as potential p53 activity modulators J. Med. Chem. 2010, 53, 8319-8329
70. Popowicz, G. M.; Czarna, A.; Wolf, S.; Wang, K.; Wang, W.; Domling, A.; Holak, T. A. Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery Cell Cycle 2010, 9, 1104-1111
71. Ma, Y.; Lahue, B. R.; Shipps, G. W.; Brookes, J.; Wang, Y. L. Substituted piperidines as HDM2 inhibitors Bioorg. Med. Chem. Lett. 2014, 24, 1026-1030
72. El-Deiry, W. S.; Tokino, T.; Velculescu, V. E.; Levy, D. B.; Parsons, R.; Trent, J. M.; Lin, D.; Mercer, W. E.; Kinzler, K. W.; Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression Cell 1993, 75, 817-825
73. Nakano, K.; Vousden, K. H. PUMA, a novel proapoptotic gene, is induced by p53 Mol. Cell 2001, 7, 683-694
74. Tovar, C.; Rosinski, J.; Filipovic, Z.; Higgins, B.; Kolinsky, K.; Hilton, H.; Zhao, X.; Vu, B. T.; Qing, W.; Packman, K.; Myklebost, O.; Heimbrook, D. C.; Vassilev, L. T. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 1888-1893
75. Weaver, J.; Downs-Kelly, E.; Goldblum, J. R.; Turner, S.; Kulkarni, S.; Tubbs, R. R.; Rubin, B. P.; Skacel, M. Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasms Mod. Pathol. 2008, 21, 943-949
76. Weaver, J.; Goldblum, J. R.; Turner, S.; Tubbs, R. R.; Wang, W. L.; Lazar, A. J.; Rubin, B. P. Detection of MDM2 gene amplification or protein expression distinguishes sclerosing mesenteritis and retroperitoneal fibrosis from inflammatory well-differentiated liposarcoma Mod. Pathol. 2009, 22, 66-70
77. Gilkes, D. M.; Pan, Y.; Coppola, D.; Yeatman, T.; Reuther, G. W.; Chen, J. Regulation of MDMX expression by mitogenic signaling Mol. Cell. Biol. 2008, 28, 1999-2010
78. Aziz, M. H.; Shen, H.; Maki, C. G. Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3 Oncogene 2011, 30, 4678-4686
79. Iancu-Rubin, C.; Mosoyan, G.; Glenn, K.; Gordon, R. E.; Nichols, G. L.; Hoffman, R. Activation of p53 by the MDM2 inhibitor RG7112 impairs thrombopoiesis Exp. Hematol. 2014, 42, 137-45 e5